$MNPR

$71.84 +$1.30 (1.84%) Close

$MNPR Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$MNPR Management Team

Dr. Christopher Starr

Executive Chairman of the Board

Age 73

Compensation $200.0K USD

Sex Male

Dr. Chandler Robinson

Chief Executive Officer

Director

Age 41

Compensation $1.144M USD

Sex Male

Mr. Andrew Cittadine

Chief Operating Officer

Age 53

Compensation $554.8K USD

Sex Male

Dr. Patrice Rioux

Acting Chief Medical Officer

Age 74

Compensation -

Sex Male

Mr. Quan Vu

Chief Financial Officer

Principal Accounting Officer

Age 53

Compensation -

Sex Male

Ms. Susan Rodriguez

Chief Commercial and Strategy Officer

Age -

Compensation -

Sex Female

Name / Title	Age	Compensation	Sex
Dr. Christopher Starr Executive Chairman of the Board	73	$200.0K USD	Male
Dr. Chandler Robinson Chief Executive Officer Director	41	$1.144M USD	Male
Mr. Andrew Cittadine Chief Operating Officer	53	$554.8K USD	Male
Dr. Patrice Rioux Acting Chief Medical Officer	74	-	Male
Mr. Quan Vu Chief Financial Officer Principal Accounting Officer	53	-	Male
Ms. Susan Rodriguez Chief Commercial and Strategy Officer	-	-	Female

Board of Directors

From the proxy statement filed Apr 30, 2026

Directors

serving now

Independent

4 of 6

stated in the proxy

Average tenure

7.4 years

from year joined

CEO also chairs the board

Christopher M. Starr

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Christopher M. Starr Board chair	73	2014 12 years	Independent	Plan Administrator Committee	Thiogenesis Therapeutics Corp.	Not stated
Chandler D. Robinson CEO	42	2014 12 years	Not independent	None stated	None stated	Paid as CEO
Raymond W. Anderson	84	2017 9 years	Independent	Audit Committee · Chair Compensation Committee · Chair Corporate Governance and Nominating Committee Plan Administrator Committee	None stated	$409,224
Kim R. Tsuchimoto	63	2023 3 years	Not independent	None stated	Thiogenesis Therapeutics Corp.	$389,937
Lavina Talukdar	52	2025 1 year	Independent	Audit Committee Compensation Committee Corporate Governance and Nominating Committee Plan Administrator Committee	None stated	$225,331
Arthur Klausner Leaving at the meeting	Not stated	Not stated	Independent	Audit Committee	None stated	$401,224

Nominated to join at the meeting

Not on the board yet; they join only if elected.

Nicole Sweeny · 51

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 30, 2026

Tactic Pharma LLC

Chandler D. Robinson, Monopar's Chief Executive Officer and a member of the Board of Directors, is a minority owner and non-controlling Managing Member of Tactic Pharma

$35 million

2025

Share repurchase: the Company repurchased 550,229 shares of its Common Stock from Tactic Pharma at the public offering price less underwriting discounts and commissions, using $35 million of September 2025 offering proceeds.

With Monopar Open in proxy

Comments

Company Executives

$MNPR Management Team

Dr. Christopher Starr

Dr. Chandler Robinson

Mr. Andrew Cittadine

Dr. Patrice Rioux

Mr. Quan Vu

Ms. Susan Rodriguez

Board of Directors

Related-party transactions